Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Proteome Sciences plc (PMSNF)
Cobham, SU, GB
Proteome Sciences Plc is a provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development. The company focuses on developing proprietary protein biomarkers for neurological diseases, oncology, and organ transplant rejection. Proteome Sciences was founded on December 10, 1993 and is headquartered in Cobham, the United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -50.00% | -33.33% | -50.00% | -60.00% | -76.27% | -80.00% | -90.91% | -98.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Specialties: +8.3%-23.2% Q4'25: +4.4% (vs Q4'23)
-
EPS growth Medical - Specialties: +10.1%+9.6% Q4'25: +50.8% (vs Q4'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%-28.9% Q4'25: +42.8% (vs Q4'23)
-
EBIT margin Medical - Specialties: +12.6%-71.0% Q4'25: -55.0% (vs Q4'23)
-
ROIC Medical - Specialties: +6.6%-48.9% Q4'25: -46.4% (vs Q4'23)
-
Share dilution Medical - Specialties: 0.0%+0.0% ★ Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-9.06× Q4'25: -7.41× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
19.64B
est: 1.90M (+1,036,317.3%)
|
19.82B
est: 2.76M (+718,617.4%)
|
18.93B
est: 3.26M (+579,961.3%)
|
19.67B
est: 2.84M (+691,555.3%)
|
19.73B
est: 3.92M (+503,051.8%)
|
4.89M
est: 2.24M (+118.4%)
|
3.76M
est: 2.51M (+49.5%)
|
3.21M
3.21M – 3.21M
+27.9% YoY
|
2.84M
2.84M – 2.84M
-11.7% YoY
|
3.74M
3.74M – 3.74M
+31.8% YoY
|
| EBITDA |
-2.68M
est: -203.2K (-1,219.7%)
|
-2.13M
est: -295.6K (-621.6%)
|
-1.48M
est: -349.8K (-321.7%)
|
-1.14M
est: -304.8K (-274.3%)
|
388.0K
est: -420.4K (+192.3%)
|
-1.52M
est: -447.2K (-238.7%)
|
-1.74M
est: -502.2K (-246.4%)
|
-642.1K
-642.1K – -642.1K
-27.9% YoY
|
-566.7K
-566.7K – -566.7K
+11.7% YoY
|
-746.7K
-746.7K – -746.7K
-31.8% YoY
|
| EBIT |
-3.08M
est: -304.6K (-910.0%)
|
-2.69M
est: -443.1K (-506.1%)
|
-1.81M
est: -524.4K (-244.6%)
|
-1.37M
est: -457.0K (-199.8%)
|
299.0K
est: -630.2K (+147.4%)
|
-2.35M
est: -677.3K (-247.3%)
|
-2.67M
est: -760.5K (-250.5%)
|
-972.4K
-972.4K – -972.4K
-27.9% YoY
|
-858.3K
-858.3K – -858.3K
+11.7% YoY
|
-1.13M
-1.13M – -1.13M
-31.8% YoY
|
| Net Income |
-2.72M
est: -4.42M (+38.5%)
|
-2.28M
est: -2.38M (+4.1%)
|
-2.50M
est: -1.50M (-65.9%)
|
-1.31M
est: -1.96M (+33.0%)
|
149.0K
est: -1.22M (+112.2%)
|
-3.41M
est: -5.21M (+34.7%)
|
-3.06M
est: -2.17M (-41.3%)
|
-1.48M
-1.48M – -1.48M
+31.6% YoY
|
-1.95M
-1.95M – -1.95M
-31.8% YoY
|
-1.16M
-1.16M – -1.16M
+40.6% YoY
|
| SGA |
4.17M
est: 480.9K (+767.5%)
|
4.24M
est: 699.8K (+505.2%)
|
4.01M
est: 828.1K (+384.0%)
|
3.24M
est: 721.6K (+348.8%)
|
2.66M
est: 995.1K (+166.8%)
|
3.02M
est: 765.5K (+294.9%)
|
1.66M
est: 859.6K (+93.0%)
|
1.10M
1.10M – 1.10M
+27.9% YoY
|
970.0K
970.0K – 970.0K
-11.7% YoY
|
1.28M
1.28M – 1.28M
+31.8% YoY
|
| EPS |
-0.01
est: -0.01 (+17.8%)
|
-0.01
est: -0.01 (-19.2%)
|
-0.01
est: -0.01 (-66.7%)
|
0.00
est: -0.01 (+33.7%)
|
0.00
est: 0.00 (+112.1%)
|
-0.01
est: -0.02 (+34.9%)
|
-0.01
est: -0.01 (-41.8%)
|
-0.01
-0.01 – -0.01
+31.6% YoY
|
-0.01
-0.01 – -0.01
-31.8% YoY
|
0.00
0.00 – 0.00
+40.6% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ian H. Pike | Chief Scientific Officer & Executive Director | 244.6K | — |
| Richard Paul Dennis | Chief Commercial Officer & Executive Director | 217.8K | male |
| Christopher Donovan James Pearce | Executive Chairman | 76.4K | male |
| Victoria Birse | Company Secretary | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PMSNF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
